Uncategorized
Noveome initiates phase 2 clinical trial for allergic conjunctivitis
Noveome Biotherapeutics Inc. announced the initiation of a phase 2 clinical trial of ST266, the company’s novel secretome for treating patients with allergic conjunctivitis, according to a press release.ST266 harnesses paracrine signaling and has been found to help promote cellular homeostasis, modulate inflammation and regenerate damaged cells, according to the company.